Last reviewed · How we verify
R256918
At a glance
| Generic name | R256918 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes (PHASE2)
- A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients (PHASE2)
- A Study of the Safety of R256918 in Obese Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R256918 CI brief — competitive landscape report
- R256918 updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI